Boston, MA -- (SBWIRE) -- 08/29/2012 -- This report covers antihypertensives, antidyslipidemics, and antithrombotics, which are the three leading categories of cardiovascular therapies by sales. Current and forecast sales of leading established brands in these categories are provided. Growth brands, key drug classes, and leading players through to 2017 are identified. Major pipeline products are profiled including estimated filing year.

Scope

- Identify growth brands, key drug classes, and leading players through to 2017.
- Review sales forecasts to 2017 for leading products, with analysis of key growth drivers and resistors across the seven major pharmaceutical markets.
- Evaluate the commercial impact of recently completed and ongoing clinical trials.
- Assess the target populations, market potential, and forecast approval dates of major pipeline products.
- Understand the present unmet needs, treatment guidelines, and the epidemiology of cardiovascular disease.

View Full Report Details and Table of Contents

Highlights

Antihypertensives are the largest drug category within the cardiovascular market by sales, but this category will undergo significant value erosion by 2017, principally due to increasing generic competition in the angiotensin receptor blockers class, which accounted for 70% of total antihypertensive sales in 2011

The value of the antidyslipidemic class will fall to around $8.2bn in 2017, partly due to the loss of exclusivity of Lipitor, previously the world's best-selling drug. The availability of generic atorvastatin will halt Crestor sales growth up to loss of exclusivity.

Novel oral anticoagulants are likely to be the fastest growing class of antithrombotics over the forecast period, driven by sales of Boehringer Ingelheim's Pradaxa, Bayer's Xarelto, and Pfizer/Bristol-Myers Squibb's Eliquis.

Reasons to Get this Report

- How does the market outlook vary for the antihypertensives, antidyslipidemics, and antithrombotics categories up to 2017?
- What are the key growth brands?
- Which were the most important companies in the cardiovascular market in 2011?
- How will the loss of exclusivity of leading brands shape the cardiovascular market, and can pipeline products compensate for these lost sales?
- Which novel therapeutics offer significant potential for future growth?

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Spain Cardiovascular Devices Market Outlook to 2017 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Prosthetic Heart Valves, Electrophysiology and Others
- Cardiovascular Monitoring and Diagnostic Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
- Cardiovascular Surgery Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
- Denmark Cardiovascular Devices Market Outlook to 2017 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Prosthetic Heart Valves, Electrophysiology and Others
- Taiwan Cardiovascular Devices Market Outlook to 2017 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Prosthetic Heart Valves, Electrophysiology and Others
- Brazil Cardiovascular Devices Market Outlook to 2017 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Prosthetic Heart Valves, Electrophysiology and Others
- Cardiovascular Prosthetic Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
- Republic of Korea Cardiovascular Devices Market Outlook to 2017 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Prosthetic Heart Valves, Electrophysiology and Others
- New Zealand Cardiovascular Devices Market Outlook to 2017 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Prosthetic Heart Valves, Electrophysiology and Others
- Saudi Arabia Cardiovascular Devices Market Outlook to 2017 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Prosthetic Heart Valves, Electrophysiology and Others